Table III.
Serum pre-procedural and post-procedural hsTnT concentrations and incidence of mild-moderate PMI and severe PMI in patient subgroups according to demographic and clinical characteristics
| Parameter | Pre-PCI hsTnT [ng/l] Median (25–75%) |
Post-PCI hsTnT [ng/l] Median (25–75%) |
Mild-moderate PMI n (%) |
Severe PMI n (%) |
|---|---|---|---|---|
| All patients (n = 304): | 9.6 (7.1–12.3) | 19.4 (12.0–38.8)* | 150 (49.3) | 37 (12.2) |
| Male (n = 204) | 9.3 (7.0–12.2) | 19.5 (11.4–36.4)* | 97 (47.5) | 25 (12.3) |
| Female (n = 100) | 9.8 (7.5–12.5) | 19.0 (12.7–40.5)* | 53 (53.0) | 12 (12.0) |
| Smokers (n = 81) | 9.2 (7.2–12.4) | 19.6 (11.0–38.2)* | 36 (44.4) | 13 (16.4) |
| Non-smokers (n = 223) | 9.6 (7.1–12.0) | 19.2 (12.2–38.8)* | 115 (51.6) | 24 (10.7) |
| Diabetic (n = 107) | 9.1 (6.9–12.4) | 20.2 (11.9–41.7)* | 56 (52.3) | 11 (10.3) |
| Non-diabetic (n = 197) | 9.8 (7.4–12.0) | 17.4 (12.2–29.3)* | 94 (47.7) | 26 (13.2) |
| Normotensive (n = 102) | 8.3 (6.9–11.6) | 22.0 (11.9–41.7)* | 48 (47.1) | 13 (12.7) |
| Hypertensive (n = 202) | 9.9 (7.3–12.3) | 18.9 (12.0–31.7)* | 102 (50.5) | 24 (11.9) |
| Previous MI (n = 62) | 9.0 (6.5–11.6) | 22.7 (12.9–44.3)* | 32 (51.6) | 7 (11.2) |
| No previous MI (n = 242) | 9.8 (7.3–12.3) | 19.3 (11.6–38.0)* | 119 (49.2) | 29 (12.0) |
| Previous PCI (n = 71) | 10.8 (7.8–13.0) ¶ | 20.9 (12.9–41.3)* | 38 (53.5) | 9 (12.7) |
| No previous PCI (n = 233) | 9.2 (6.9–11.8) | 19.2 (11.4–36.7)* | 112 (48.1) | 28 (12.0) |
| Previous CABG (n = 29) | 11.0 (9.0–12.9) | 26.6 (19.7–57.9)* ¶ | 22 (75.9) | 3 (10.4) |
| No previous CABG (n = 275) | 9.2 (7.1–12.0) | 18.7 (11.5–36.6)* | 128 (46.5) | 34 (12.4) |
| Statin user (n = 134) | 9.9 (7.5–12.1) | 19.7 (11.7–39.5)* | 72 (53.7) | 15 (11.2) |
| Non-user (n = 170) | 9.3 (6.9–12.8) | 19.3 (12.2–37.0)* | 78 (45.9) | 22 (12.9) |
| β-Blocker user (n = 194) | 9.8 (6.9–12.5) | 19.8 (12.5–40.4)* | 102 (52.6) | 23 (11.9) |
| Non-user (n = 110) | 9.6 (7.7–12.2) | 18.9 (11.4–33.8)* | 48 (43.6) | 14 (12.7) |
| ACEI/ARB user (n = 174) | 10.5 (7.6–12.9) ¶ | 19.6 (12.8–35.0)* | 98 (56.3) | 20 (11.5) |
| Non-user (n = 130) | 8.3 (6.9–11.3) | 19.0 (10.2–39.3)* | 52 (40.0) | 17 (10.0) |
Pre-PCI hsTnT – Pre-procedural serum high-sensitivity troponin T level, post-PCI hsTnT – post-procedural serum high-sensitivity troponin T level, PMI – periprocedural myocardial injury, MI – myocardial infarction, PCI – percutaneous coronary intervention, CABG – coronary artery bypass grafting, ACEI/ARB – angiotensin-converting enzyme inhibitors-angiotensin receptor blockers. Data are median (interquartile range) or number of patients (percentage).
Significantly higher than the respective values of pre-PCI hsTnT concentrations.
Significantly higher than the values observed in the respective group.